Cancer cachexia and anabolic interventions: a case report
| Autor: | Melinda Sheffield-Moore, Kathleen M. Randolph, William J. Durham, Edgar L. Dillon, Randall J. Urban, Astrid M. Horstman, Gwyn Richardson, Maurice Willis, Gurjot Basra, Concepcion Diaz-Arrastia, Shanon L. Casperson, Sandra S. Hatch, Lyuba Levine |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Quality of life medicine.medical_specialty Anabolism Psychological intervention Clinical nutrition 03 medical and health sciences 0302 clinical medicine Physiology (medical) Internal medicine otorhinolaryngologic diseases medicine Orthopedics and Sports Medicine Testosterone Wasting Fatigue 030304 developmental biology Cervical cancer 0303 health sciences business.industry Cancer medicine.disease Molecular medicine 3. Good health Endocrinology Lean body mass 030220 oncology & carcinogenesis Amino acids Original Article medicine.symptom business psychological phenomena and processes |
| Zdroj: | Journal of Cachexia, Sarcopenia and Muscle |
| ISSN: | 2190-6009 |
| Popis: | Background Standard-of-care (SOC) cancer treatments are primarily aimed at reducing size and progression of a tumor. There is a need for successful supplemental anabolic therapies to combat cancer cachexia in addition to these SOC treatment modalities. Anabolic interventions, including testosterone and amino acid supplements, may be beneficial in reducing and/or reversing muscle wasting in these patient populations. Methods A 48-year-old Caucasian female with recurrent cervical cancer was scheduled to receive three 21-day cycles of cisplatin and topetecan chemotherapy. She qualified, consented, and enrolled into a blinded interventional pilot study where she received daily whey protein (10 g, three times per day with meals) and a weekly injection of testosterone enanthate (100 mg intramuscular) before and during the SOC chemotherapy treatment period. Body composition, serum inflammatory markers, mixed muscle protein synthesis and breakdown rates, physical function, fatigue, and quality of life were assessed before and after the intervention period. Results Body composition, as assessed by an increase in body weight and lean body mass and reduction in fat mass; physical function; fatigue; and quality of life each improved across the entire intervention period despite general increases in inflammatory markers and no improvements in muscle protein turnover towards the end of the intervention. Conclusions Concomitant treatment of oral amino acids and testosterone may be a viable therapeutic option for fighting cachexia and improving body composition and quality of life during chemotherapeutic treatment of recurrent cervical cancer. These positive outcomes may be attainable over time despite overall poor inflammatory status. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink